With rapid advances being made in Advanced Therapy Medicinal Products, or ATMPs, (medicines for human use based on genes, tissues or cells) and a frequently changing regulatory environment, those working in pharmaceutical aseptic manufacturing face an exciting and challenging period of expansion. Global growth in the use of personalised medicines means the industry has to respond to demand for faster turnaround, compliant sterile environments and cost-effective containment solutions.

Whether you’re involved in small batch aseptic filling for clinical trials or late phase/commercial manufacturing of medicines in liquid vials, syringes or IV bags, operator and product protection is vital. This is especially true when handling the new generation of High Potent Active Pharmaceutical Ingredients (HPAPIs) most frequently used in oncology treatments in the form of Antibody Drug Conjugates (ADCs) as well as in hormonal drugs and glaucoma treatments.

The aseptic manufacturing market is forecast to grow to $500 billion by 2025, and those at the forefront of this growth are already capitalising on new technologies that can drive efficiencies in Grade A environments.